ScinoPharm Reports Record-High Performance.Profits and Revenue in First Nine Months of 2007 Already Surge Past Record 2006 Performance TAIPEI, Taiwan -- Active pharmaceutical ingredient (API (Application Programming Interface) A language and message format used by an application program to communicate with the operating system or some other control program such as a database management system (DBMS) or communications protocol. ) specialist ScinoPharm reported record revenue and profits for the first nine months of 2007, ended 30 September 2007. Highlights: * Total revenue for Jan-Sept 2007 surged to $46.7 million. To-date revenue has already exceeded entire 2006 record revenue of $44.9 million. * Jan-Sept 2007 revenue of $46.7 million, an increase of 48 percent from $31.5 million in Jan-Sept 2006. * Net income (before taxes) grew to record $7.7 million, an increase of over 600% from $1.1 million in Jan-Sept 2006. * To-date 2007 net income is already 3 times total 2006 net income. * September 2007 sales reached $9.7 million, highest in the company's 10-year history. "Our business strategy, which is focused on building a strong portfolio of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. products and a growing base of global customers, continues to drive record performance," said Dr. Jo Shen Shen, in the Bible, place, perhaps close to Bethel, near which Samuel set up the stone Ebenezer. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ScinoPharm. "Other factors, including steadier revenue streams from more commercialized products, and improved margins and reduced costs in manufacturing, also contributed to the company's strong results." ScinoPharm, specializing in cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic and high potent APIs, has
grown from a regional to a global API manufacturer with significant
market presence in the supply of oncology APIs worldwide.
To acquire new orders, the company has acted swiftly in worldwide regulatory registrations of the drug master file Drug Master File or DMF is a document prepared by a manufacturer in the pharmaceutical industry and submitted solely at his discretion to the Food and Drug Administration (FDA). There is no requirement by law or FDA regulation to present a DMF. (DMF (Distribution Media Format) A floppy disk format from Microsoft that was used to distribute its software. DMF floppies compressed more data (1.7MB) onto the 3.5" diskette, and the files could not be copied with normal DOS and Windows commands. A DMF utility had to be used. ) for its APIs. ScinoPharm recently completed one additional US DMF registration for its oncology API Topotecan topotecan /to·po·te·can/ (to?po-te´kan) an antineoplastic that inhibits DNA topoismerase; used as the hydrochloride salt in the treatment of metastatic ovarian carcinoma and small cell lung carcinoma. HCl, bringing its total US regulatory registrations to 23 and worldwide registrations to over 240. About ScinoPharm Taiwan ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a full spectrum of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The company currently serves more than 160 customers worldwide. To date, it has over 240 DMF registrations worldwide, 23 of which were filed in the US. For more information, please visit the company's web site at http://www.scinopharm.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion